Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
about
Proteomic-Based Approaches for the Study of Cytokines in Lung CancerInterplay between Cellular and Molecular Inflammatory Mediators in Lung CancerNovel Drugs and Combination Therapies for the Treatment of Metastatic MelanomaAntibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy.Immunological effects of vaccines combined with granulocyte colony-stimulating factor on a murine WEHI-3 leukemia model.Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases.Novel targeted therapies in adrenocortical carcinoma.Advances in immunotherapy for melanoma management.Potential role of immunotherapy in advanced non-small-cell lung cancerA meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer.Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in contextThe Emerging Role of PD-1/PD-L1-Targeting Immunotherapy in the Treatment of Metastatic Urothelial Carcinoma.Human papillomavirus type 16 E6 oncoprotein promotes proliferation and invasion of non-small cell lung cancer cells through Toll-like receptor 3 signaling pathway.Immuno-oncology for renal cell carcinoma treatment: future perspectives for combinations and sequences with molecularly targeted agents.Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy.Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis.Next generation predictive biomarkers for immune checkpoint inhibition.Dermatologic adverse events of checkpoint inhibitors: what an oncologist should know.The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction.[Adverse effects of immunotherapy : Clinical aspects, radiological and nuclear medicine results].Inherited functional variants of the lymphocyte receptor CD5 influence melanoma survival.Imaging Features of Toxicities by Immune Checkpoint Inhibitors in Cancer Therapy.Identification and Validation of a PD-L1 Binding Peptide for Determination of PDL1 Expression in Tumors.Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse.Primary hypothyroidism and isolated ACTH deficiency induced by nivolumab therapy: Case report and review.Effect and safety of cytokine-induced killer (CIK) cell immunotherapy in patients with breast cancer: A meta-analysis.Case report on the role of radiofrequency-assisted spleen-preserving surgery for splenic metastasis in the era of check-point inhibitors.Immune-related adverse events associated with PD-1 and PD-L1 inhibitors for nonsmall cell lung cancer: Protocol for a systematic review and meta-analysis.Programmed cell death ligands expression in phaeochromocytomas and paragangliomas: Relationship with the hypoxic response, immune evasion and malignant behavior.Therapeutic vaccines for high-risk HPV-associated diseases.Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy as second-line therapy of cytotoxic anticancer drugs in patients with advanced non-small cell lung cancer.Exacerbation of autoimmune hemolytic anemia induced by the first dose of programmed death-1 inhibitor pembrolizumab: a case report.Current and emerging EGFR therapies for glioblastoma.Autoimmune comorbidities in patients with metastatic melanoma: a retrospective analysis of us claims data.Posttranscriptional Control of PD-L1 Expression by 17β-Estradiol via PI3K/Akt Signaling Pathway in ERα-Positive Cancer Cell Lines.Primary adrenal malignant melanoma: A case report and review of literature.Diffuse edema suggestive of cytokine release syndrome in a metastatic lung carcinoma patient treated with pembrolizumab.Renal Tubular Acidosis an Adverse Effect of PD-1 Inhibitor Immunotherapy.Bayesian adaptive clinical trials of combination treatments.Pathogenic role for macrophage migration inhibitory factor in glioblastoma and its targeting with specific inhibitors as novel tailored therapeutic approach.
P2860
Q26738539-81CD5DC5-5B29-407F-AC30-98D87EC42C0EQ26768652-73581143-3337-4CF6-A25B-7B7E94C5CA5EQ26772015-31AF8940-23D4-46DC-A0A1-9D1CEA87EE09Q30275229-0F3ECFA5-574F-4CDF-B229-12484ED0602BQ33597774-A58A29CE-77EA-4324-8D57-CB5C97AA243AQ37135023-80AA9572-3483-4A5F-BB18-9B23E47AA1ECQ37233378-8D6E9EAA-0159-4C83-BB8D-ED175FD2A220Q37375978-3B685672-D2DA-4D02-8CA6-87A2C73696DDQ37527869-46922DB2-2C9F-49C8-9BEB-E4AEEA76098FQ37552085-2001F6E2-4D3D-4F4A-868F-FFC7297C4F0BQ37669352-4B7C0739-4EB3-49C7-B1A7-F555594D20E9Q38612965-6A852620-19E7-406D-A5D9-1E45255152A2Q38704376-834CF223-30EC-4A9F-9E2F-E38F9E693D38Q38783324-5230A54C-C8AB-4F0F-8FF1-EB5B7C8BACA6Q38826536-CC14182B-C129-4C63-B553-8CBB97CADE0CQ38898344-420EE907-4C53-4031-BB4E-F4422AFD442DQ39016247-EF2CB305-B9BB-451B-B1E9-CF5608A4450BQ39045600-7DA68E36-2C4A-4245-9F38-C486A0DE1E29Q39518049-51FFF2A3-6024-413B-A46B-32DA076472EAQ40124225-95FAAC74-8CE9-41A7-8EAB-1A78ED401F87Q40759062-37FB258F-D464-40E4-8741-C5457278CB71Q41669891-7B007E03-BB75-40AC-A72F-D3342CEE999CQ42652839-BE647E85-5BB2-4C3C-A5CB-9274781A3D39Q42801569-B7BD81D4-EC56-47F0-BAF3-602C69A436CBQ47111469-F699C227-0FE6-4262-B76B-58D69227C257Q47128387-3C9F7939-E77E-422F-B902-83E2E9BBF53AQ47149194-025F6B5E-6D59-421F-B8F0-62304F88E407Q47165337-424578E6-FCDB-4784-BD38-73B10D475176Q47181092-FA6D9FEC-C931-4BE1-B29D-57399B51ACEAQ47255618-18C40DBA-A82E-4C79-A7F7-B3DC4E338BC5Q47640288-C33AAB4A-14CA-4E4A-A588-D21994083515Q47655098-5D5C4393-BA08-4B57-9E5F-1A949DDEF56CQ47878958-1BBA950E-5F77-4354-BC68-41A940BEE17DQ49166546-9E883701-95C7-4781-A545-A0D40254726AQ49214132-BD6F79EB-06B4-4765-8845-B94C5C6A8226Q49486898-4D7013BB-4C70-4307-96F2-08C4B250453CQ51095574-A7F88518-1D4B-4810-896A-516766C7403BQ52318577-0857C190-7BB2-4A66-9CDE-64C3EDB84885Q52562503-08FBB8AC-C441-4C44-BD0D-7A42B78DDDBCQ52715769-2C9F645D-11AA-47AD-B366-8E77BEA87135
P2860
Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
@en
type
label
Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
@en
prefLabel
Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
@en
P2093
P2860
P356
P1433
P1476
Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
@en
P2093
Cindy Huynh
Devin B Lowe
Gary W Jean
P2860
P304
P356
10.1002/PHAR.1643
P407
P577
2015-10-01T00:00:00Z